Related Experiment Video
Updated: Apr 6, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
Published on: April 9, 2014
Use of Integrase Inhibitors in HIV-Infected Children and Adolescents
Walter Dehority1, Jacobo Abadi, Andrew Wiznia
1Division of Infectious Diseases, Department of Pediatrics, The University of New Mexico, MSC10 5590, 1 University of New Mexico, Albuquerque, NM, 87131-0001, USA, WDehority@salud.unm.edu.
Abstract:
Resistance to antiretroviral drugs is an increasingly prevalent challenge affecting both the adult and pediatric HIV-infected populations. Though data on the safety, pharmacokinetics, and efficacy of newer antiretroviral agents in children typically lags behind adult data, newer agents are becoming available for use in HIV-infected children who are failing to respond to or are experiencing toxicities with traditional antiretroviral regimens. Integrase strand transfer inhibitors are one such new class of antiretrovirals. Raltegravir has been US Food and Drug Administration (FDA) approved for use in patients over the age of 4 weeks. Elvitegravir is a second member of this class, and has the potential for use in children but does not yet have a Pediatric FDA indication. Dolutegravir, a second-generation integrase inhibitor, is approved for those older than 12 years. This review summarizes the use of integrase inhibitors in children and adolescents, and highlights the results of recent clinical trials.
Related Concept Videos
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Pharmacokinetics in Pediatric Patients: Drug Excretion
Sexually Transmitted Infections
Retroviruses
Subviral Agents

